Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company focused on developing novel serotonergic agonists (NSAs), announced that Chief Medical Officer Amir Inamdar will participate in a fireside chat at the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference. The conference is scheduled for June 15-16, 2026, and the fireside chat will be available on demand beginning June 15 at 7:00 a.m. EDT.
The announcement underscores Helus Pharma's commitment to advancing its pipeline of proprietary NSAs, which are synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. The company aims to address the large unmet need for individuals suffering from depression, anxiety, and other mental health conditions. Helus Pharma is currently developing HLP003, a proprietary NSA in Phase 3 clinical development for the adjunctive treatment of major depressive disorder, which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, HLP004, another proprietary NSA, is in Phase 2 for generalized anxiety disorder. The company also has an extensive research portfolio of investigational NSAs.
The participation in the H.C. Wainwright conference provides a platform for Helus Pharma to discuss its clinical programs and the potential of its NSA platform. The company's focus on neuroplasticity and serotonin pathways represents a novel approach to treating mental health conditions, which could offer durable improvements for patients. Helus Pharma operates in Canada, the United States, the United Kingdom, and Ireland. For more information, visit the company's website at www.helus.com or follow the team on X, LinkedIn, YouTube, and Instagram. The full press release is available at https://ibn.fm/KsnJW.
The news of the conference participation is important as it highlights the ongoing development of Helus Pharma's NSA pipeline, which has the potential to transform the treatment landscape for major depressive disorder and generalized anxiety disorder. With Breakthrough Therapy Designation for HLP003, the company is positioned to address significant unmet needs in mental health care. Investors and stakeholders can gain insights into the company's strategy and clinical progress through the fireside chat.
